Amaryl® (glimepiride) is an oral antidiabetic agent indicated for the treatment of type 2 diabetes in conjunction with a dietary regimen and physical exercise. Amaryl reduces blood glucose levels via dual mode of action: by helping the body to produce insulin and by reducing insulin resistance. It provides control on glucose level. The most common adverse event is hypoglycemia.
Amaryl was registered in Hong Kong in 1997.
Reference: Amaryl Hong Kong Prescribing Infomation
Apidra (insulin glulisine)
Apidra® is a rapid-acting insulin, used to reduce high blood sugar in patients with diabetes mellitus; it may be given to adults, adolescents and children, 6 years of age and older. Apidra was approved by the EMEA and FDA in September 2004 and April 2004 respectively.
SoloSTAR® is an easy-to-use disposable pen for the administration of Apidra. It uses a simple, intuitive design that featured easy-to-read display and simple steps to operate. The unique stylish design received a 2007 Good Design award from the Chicago Athenaeum Museum of Architecture and Design.
Reference: Apidra Hong Kong Prescribing Infomation
Lantus (insulin glargine 100 unit/mL)
Lantus® (insulin glargine) is an insulin analog with a prolonged action, administered once a day by subcutaneous injection. It is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Lantus is the first basal insulin offering 24-hour peak-less efficacy. It can be taken once daily at any time of the day.
Lantus SoloSTAR® is a new, easy-to-use disposable pen for administration of Lantus. SoloSTAR, allows to administer doses from 1 up to 80 units, in one unit increment, in one injection. It is small, discreet and eliminates the need for the patient to change insulin cartridges. Its unique stylish design received a 2007 Good Design award from the Chicago Athenaeum Museum of Architecture and Design.
Reference: Lantus Hong Kong Prescribing Infomation
Lyxumia® is a once-daily prandial glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of adult patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal. It is known to suppress glucagon secretion from pancreatic alpha cells and stimulate glucose-dependent insulin secretion by pancreatic beta cells. Lyxumia increases glucose-dependent insulin release, decreased glucagon secretion, and slows gastric emptying.
The cardiovascular safety of Lyxumia is confirmed by the ELIXA study in 2015. Its achievement in glycemic targets with fewer hypoglycemic events and no weight gain in addition to basal insulin versus rapid acting insulin, make it a meaningful basal intensification alternative in uncontrolled basal insulin-treated type 2 diabetes.
Lyxumia was approved in Europe in 2013. It also got U.S. Food & Drug Administration (FDA) approval in July 2016 under a different trade name, Adlyxin.
Reference: 1. Lyxumia Hong Kong Prescribing Information | 2. Rosenstock et al. Diabetes Care. 2016 Aug;39(8):1318-28.
Toujeo (insulin glargine 300 unit/mL)
Toujeo® is newer generation of long-acting insulin used to treat adults with type 2 and type 1 diabetes for the control of high blood sugar. Toujeo comes from the makers of Lantus®. Toujeo offers more gradual release of insulin, it helps to provide comparable glycemic control with lower risk of hypoglycemia episodes1. One unit of Toujeo has the same amount of insulin as one unit of Lantus — but with one-third the injection volume.
Toujeo is available in Toujeo SoloSTAR®. The volume per pen has 450 units and the maximum single injection dose is 80 IU.
Toujeo was approved in Europe in May 2014. It also got U.S. Food & Drug Administration (FDA) approval in Feb 2015.
Reference: Toujeo Hong Kong Prescribing Infomation